

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/822,379	03/30/2001	Philip Stewart Low	3220-67883 5816	
23643 7	7590 07/02/2002			
BARNES & THORNBURG			EXAMINER	
11 SOUTH MERIDIAN INDIANAPOLIS, IN 46204		CANELLA, KAREN A		
			ART UNIT	PAPER NUMBER
			1642	7
			DATE MAILED: 07/02/2002	/

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STA1. DEPARTMENT OF C MMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

	STATES OF	Washington.	D.C. 20231
09/822, 379 APPLICATION NUMBER		FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER PAPER NUMBER ART UNIT

DATE MAILED:

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY	OFFICE ACTION SUMMARY				
Responsive to communication(s) filed on	,				
	and the the merits is closed in				
Since this application is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for allowance except for formal matters, prosecution is in condition for all the property of the	on as to the ments is closed in				
accordance with the practice under Ex parte Quayle, 1935 b.o. 11. A shortened statutory period for response to this action is set to expire	in the period for response will cause ined under the provisions of 37 CFR				
Disposition of Claims	is/are pending in the application.				
Disposition of Claims Claim(s) 1- 76	is/are withdrawn from consideration.				
Of the above, claim(s)	is/are allowed.				
	·····				
☐ Claim(s) are so	ubject to receive				
Application Papers					
See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.					
is/are object	is approved disapproved.				
The drawing(s) filed on	is approved				
The specification is objected to by the Examiner.					
The oath or declaration is objected to by the Examiner.					
Delegity under 35 U.S.C. § 119					
	d).				
Acknowledgement is made of a street of the CERTIFIED copies of the priority documents if	nave oeen				
PUT R	We :1.2(a)).				
to tilled copies not received:					
Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 1196	e).				
Attachment(s)					
Notice of Reference Cited, PTO-892					
Information Disclosure Statement(s), PTO-1449, Paper No(s)					
Interview Summary, PTO-413					
Notice of Draftsperson's Patent Drawing Review, PTO-948					
Tuesting of Informal Patent Application, PTO-152					
- SEE OFFICE ACTION ON THE FOLLOWING	* US 3PO-1396-410-238				

Application/Control Number: 09/822,379

Art Unit: 1642

DETAILED ACTION

Election/Restriction

- 1. This application contains claims directed to the following patentably distinct species of the claimed invention: the therapeutic factors selected from the group consiting of
 - (a) cell killing agents,
 - (b) tumour penetration enhancers,
 - (c) chemotherapeutic agents,
 - (d) anti-microbial agents,
 - (e) cytotoxic immune cells, and
 - (f) compounds capable of stimulating an endogenous immune response.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 38 and 41-43 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to

Application/Control Number: 09/822,379 Page 3

Art Unit: 1642

be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission

may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should

be directed to the Group receptionist whose telephone number is (703) 308-0196.

Naren A. Canella, Ph.D.

Patent Examiner, Group 1642

July 1, 2002